Abstract
Arterial stiffness is the most important cause of increasing systolic and pulse pressure, and for decreasing diastolic pressure with ageing. Many measures can be applied to quantify arterial stiffness, but all are approximations only, on account of the nonhomogenous structure of the arterial wall, its variability in different locations, at different levels of distending pressure, and with changes in smooth muscle tone. This article summarizes those indices with a focus on newer non-invasive methods and provides an overview of physiological, pathological and pharmacological influences on arterial hemodynamics. In the near future, the ability to detect and monitor subclinical arterial damage will improve cardiovascular risk stratification and act as a better guide in assessing the efficacy of therapeutic interventions than monitoring blood pressure alone. However, large-scale clinical trials are needed to prove the hypothesis that treatment of these new therapeutic targets will translate into clinical benefit, expressed in cardiovascular events or even mortality.
Keywords: arterial stiffness, cardiovascular drugs, arterial hemodynamics, arterial physiology
Current Pharmaceutical Design
Title: Arterial Stiffness and Cardiovascular Drugs
Volume: 9 Issue: 13
Author(s): Thomas Weber, Johann Auer, Geza Eisserer, Robert Berent, Bernd Eber and Michael F. O´Rourke
Affiliation:
Keywords: arterial stiffness, cardiovascular drugs, arterial hemodynamics, arterial physiology
Abstract: Arterial stiffness is the most important cause of increasing systolic and pulse pressure, and for decreasing diastolic pressure with ageing. Many measures can be applied to quantify arterial stiffness, but all are approximations only, on account of the nonhomogenous structure of the arterial wall, its variability in different locations, at different levels of distending pressure, and with changes in smooth muscle tone. This article summarizes those indices with a focus on newer non-invasive methods and provides an overview of physiological, pathological and pharmacological influences on arterial hemodynamics. In the near future, the ability to detect and monitor subclinical arterial damage will improve cardiovascular risk stratification and act as a better guide in assessing the efficacy of therapeutic interventions than monitoring blood pressure alone. However, large-scale clinical trials are needed to prove the hypothesis that treatment of these new therapeutic targets will translate into clinical benefit, expressed in cardiovascular events or even mortality.
Export Options
About this article
Cite this article as:
Weber Thomas, Auer Johann, Eisserer Geza, Berent Robert, Eber Bernd and O´Rourke F. Michael, Arterial Stiffness and Cardiovascular Drugs, Current Pharmaceutical Design 2003; 9 (13) . https://dx.doi.org/10.2174/1381612033455080
DOI https://dx.doi.org/10.2174/1381612033455080 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Flavonoid Antioxidants
Current Medicinal Chemistry Systemic Application of Anti-inflammatory Agents in Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Circulating Levels of Uric Acid and Risk for Metabolic Syndrome
Current Diabetes Reviews Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds High-Throughput Proteomics: A New Tool for Quality and Safety in Fishery Products
Current Protein & Peptide Science Biochemical Markers of Renal Function
Current Medicinal Chemistry Biomarkers in Aortic Valve Stenosis and their Clinical Significance in Transcatheter Aortic Valve Implantation
Current Medicinal Chemistry Synthesis of New A-CD Estrogenic Compounds: D-Homo-analogs Lacking B-ring
Current Organic Chemistry ABC Transporters and Sterol Absorption
Current Drug Targets - Cardiovascular & Hematological Disorders Hybrid Docking-QSAR Studies of 1, 4-dihydropyridine-3, 5-Dicarboxamides as Potential Antitubercular Agents
Current Computer-Aided Drug Design Genetics of Congenital Heart Disease
Current Cardiology Reviews Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety Formulation and In Vitro Evaluation of Solid Lipid Microparticles of Candesartan Cilexetil Floating Tablets
Drug Delivery Letters